Afficher la notice abrégée

Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

dc.rights.licenseopenen_US
dc.contributor.authorBOETTIGER, David C.
dc.contributor.authorNEWALL, Anthony T.
dc.contributor.authorPHILLIPS, Andrew
dc.contributor.authorBENDAVID, Eran
dc.contributor.authorLAW, Matthew G.
dc.contributor.authorRYOM, Lene
dc.contributor.authorREISS, Peter
dc.contributor.authorMOCROFT, Amanda
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorWEBER, Rainer
dc.contributor.authorEL-SADR, Wafaa
dc.contributor.authorD'ARMINIO MONFORTE, Antonella
dc.contributor.authorDE WIT, Stephane
dc.contributor.authorPRADIER, Christian
dc.contributor.authorHATLEBERG, Camilla I.
dc.contributor.authorLUNDGREN, Jens
dc.contributor.authorSABIN, Caroline
dc.contributor.authorKAHN, James G.
dc.contributor.authorKAZI, Dhruv S.
dc.date.accessioned2021-04-20T12:15:15Z
dc.date.available2021-04-20T12:15:15Z
dc.date.issued2021-03
dc.identifier.issn1758-2652 (Electronic) 1758-2652 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26983
dc.description.abstractEnBACKGROUND: Expanding statin use may help to alleviate the excess burden of atherosclerotic cardiovascular disease in people living with HIV (PLHIV). Pravastatin and pitavastatin are preferred agents due to their lack of substantial interaction with antiretroviral therapy. We aimed to evaluate the cost-effectiveness of pravastatin and pitavastatin for the primary prevention of atherosclerotic cardiovascular disease among PLHIV in the United States. METHODS: We developed a microsimulation model that randomly selected (with replacement) individuals from the Data-collection on Adverse Effects of Anti-HIV Drugs study with follow-up between 2013 and 2016. Our study population was PLHIV aged 40 to 75 years, stable on antiretroviral therapy, and not currently using lipid-lowering therapy. Direct medical costs and quality-adjusted life-years (QALYs) were assigned in annual cycles and discounted at 3% per year. We assumed a willingness-to-pay threshold of $100,000/QALY gained. The interventions assessed were as follows: (1) treating no one with statins
dc.description.abstractEn(2) treating everyone with generic pravastatin 40 mg/day (drug cost $236/year) and (3) treating everyone with branded pitavastatin 4 mg/day (drug cost $2,828/year). The model simulated each individual's probability of experiencing atherosclerotic cardiovascular disease over 20 years. RESULTS: Persons receiving pravastatin accrued 0.024 additional QALYs compared with those not receiving a statin, at an incremental cost of $1338, giving an incremental cost-effectiveness ratio of $56,000/QALY gained. Individuals receiving pitavastatin accumulated 0.013 additional QALYs compared with those using pravastatin, at an additional cost of $18,251, giving an incremental cost-effectiveness ratio of $1,444,000/QALY gained. These findings were most sensitive to the pill burden associated with daily statin administration, statin costs, statin efficacy and baseline atherosclerotic cardiovascular disease risk. In probabilistic sensitivity analysis, no statin was optimal in 5.2% of simulations, pravastatin was optimal in 94.8% of simulations and pitavastatin was never optimal. CONCLUSIONS: Pravastatin was projected to be cost-effective compared with no statin. With substantial price reduction, pitavastatin may be cost-effective compared with pravastatin. These findings bode well for the expanded use of statins among PLHIV in the United States. To gain greater confidence in our conclusions it is important to generate strong, HIV-specific estimates on the efficacy of statins and the quality-of-life burden associated with taking an additional daily pill.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHIV
dc.subject.enCardiovascular disease
dc.subject.enStatin
dc.subject.enCost‐effectiveness
dc.subject.enUnited States
dc.subject.enAntiretroviral therapy
dc.title.enCost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States
dc.title.alternativeJ Int AIDS Socen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/jia2.25690en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33749164en_US
bordeaux.journalAIDS. Official journal of the international AIDS Societyen_US
bordeaux.pagee25690en_US
bordeaux.volume24en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-03203026
hal.version1
hal.date.transferred2021-04-20T12:15:20Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=AIDS.%20Official%20journal%20of%20the%20international%20AIDS%20Society&rft.date=2021-03&rft.volume=24&rft.issue=3&rft.spage=e25690&rft.epage=e25690&rft.eissn=1758-2652%20(Electronic)%201758-2652%20(Linking)&rft.issn=1758-2652%20(Electronic)%201758-2652%20(Linking)&rft.au=BOETTIGER,%20David%20C.&NEWALL,%20Anthony%20T.&PHILLIPS,%20Andrew&BENDAVID,%20Eran&LAW,%20Matthew%20G.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_JIAS_2021_Boettiger.pdf
Taille:
597.9Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée